quiverquant.com
Cure8 news brief
Why This Matters
Positive Phase 3 data for a subcutaneous formulation of risankizumab (SKYRIZI) in Crohn’s disease could expand treatment options for people with moderate-to-severe Crohn’s and influence prescribing and insurance coverage over time.
Investors and clinicians are also watching SKYRIZI and JAK inhibitor (RINVOQ) data as drivers of AbbVie’s post‑Humira growth.
Who Should Pay Attention
Adults with moderate-to-severe Crohn’s disease, patients already on or considering biologic therapy, clinicians treating IBD, researchers tracking biologic and JAK-inhibitor development, and patient advocates following treatment access and cost trends.
Study Snapshot
Story typeBusiness news
Evidence typePhase 3 clinical trial
Source depthFull source text
What To Know
AbbVie announced new Phase 3 AFFIRM results showing subcutaneous SKYRIZI (risankizumab) had higher clinical and endoscopic response rates than placebo in adults with moderately to severely active Crohn’s disease.
The article is a market/stock-movement write-up (Quiver Quantitative) linking the positive Phase 3 data and supportive analyst commentary to AbbVie’s share-price rise; it cites AbbVie and SEC filings as sources.
Keep In Mind
This is a financial-news summary linking trial results to stock movement; it does not present full trial data or peer-reviewed publication. The article references an Oct 13 press release of Phase 3 AFFIRM results but does not include detailed efficacy or safety numbers.
Regulatory decisions, guideline changes, and payer coverage typically follow independent peer review and regulatory review.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationquiverquant.com
AuthorsQuiver PriceTracker
Indexed viaGoogle News
Source typeWeb article
PublishedOct 14, 2026, 2:54 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Did SKYRIZI's Subcutaneous Crohn's Data Just Shift AbbVie's (ABBV) Immunology ...
A Phase 3 positive result for subcutaneous SKYRIZI could expand treatment options for people with Crohn’s disease by offering a more convenient dosing route and may affect how available drugs like Rinvoq are used. It...
New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate ...
New Phase 3 and long‑term analyses presented at ACG 2026 report that risankizumab and upadacitinib showed disease control in patients with moderate‑to‑severe IBD, including difficult‑to‑treat Crohn’s disease. These...
Subcutaneous Guselkumab Proves Efficacious for IBD in Two Studies: ASTRO and GRAVITI
These are phase 3 results showing subcutaneous guselkumab helped more people reach clinical and endoscopic goals than placebo in moderate-to-severe UC and Crohn’s disease; a fully subcutaneous option could offer more...